146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC

Perigon Wealth Management LLC bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 146,185 shares of the company's stock, valued at approximately $1,944,000. Perigon Wealth Management LLC owned approximately 0.28% of 4D Molecular Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at about $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics during the third quarter worth about $41,000. AQR Capital Management LLC purchased a new position in 4D Molecular Therapeutics in the first quarter valued at about $46,000. Daiwa Securities Group Inc. increased its holdings in 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company's stock valued at $48,000 after buying an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter valued at approximately $48,000. 99.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on FDMT shares. Chardan Capital upgraded 4D Molecular Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group reiterated a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.62.

Insider Buying and Selling

In related news, insider David Kirn sold 12,415 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the sale, the insider owned 871,737 shares in the company, valued at approximately $8,760,956.85. This trade represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company's stock, valued at $103,404. The trade was a 53.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 200,496 shares of company stock worth $2,240,244. 7.90% of the stock is owned by company insiders.

4D Molecular Therapeutics Trading Up 19.4%

Shares of FDMT stock opened at $14.55 on Tuesday. The firm has a 50-day moving average price of $11.06 and a 200 day moving average price of $9.93. 4D Molecular Therapeutics, Inc. has a twelve month low of $5.97 and a twelve month high of $15.03. The company has a market capitalization of $760.67 million, a price-to-earnings ratio of -5.53 and a beta of 2.73. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to analysts' expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source